Cardiovascular Disease (CVD) in Type Segment to Lead Market during 2021–2028
According to our new research study on “Cardiometabolic Diseases Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Treatment, Dosage, Route of Administration, End Users, and Distribution Channel,” the market is expected to grow from US$ 93,494.41 million in 2021 to US$ 121,804.49 million by 2028 in 2021; it is estimated to grow at a CAGR of 3.9% during 2021–2028. The report highlights trends prevailing in the market and factors driving its growth. The market growth is mainly attributed to factors such as increasing prevalence of cardiometabolic diseases and innovation in CMDs therapeutics. However, the under diagnosis of CVDs in low- and middle-income countries (LMICs) is hampering the growth of the market.
Based on type, the cardiometabolic diseases market is segmented into cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. The cardiovascular disease (CVD) segment held the largest share of the market in 2021, and the segment is anticipated to register the highest CAGR in the market during the forecast period. CVDs are a group of conditions of the heart and blood vessels. Types of CVDs are coronary heart disease, cerebrovascular disease, heart failure, congenital heart disease, deep vein thrombosis, peripheral arterial disease, and rheumatic heart disease. Heart attacks and strokes are acute events caused by a blockage that prevents blood from flowing to the heart or brain. Congestive heart failure (CHF) happens when the heart's function as a pump is inadequate to meet the body's needs. Common causes of heart failure are coronary artery disease, high blood pressure, and diabetes. As per Emory Healthcare, ~550,000 new cases of CHF are diagnosed in the US each year.
Impact of COVID-19 Pandemic on Cardiometabolic Diseases Market:
The COVID-19 pandemic is adversely affecting industries worldwide. The outbreak led to significant disruptions in primary industries, such as manufacturing, healthcare, energy & power, electronics & semiconductor, aerospace & defense, and construction, in 2020. However, it provided a vital growth opportunity to the cardiovascular diseases market players. As per the Cleveland Clinic, ~15% of patients suffering from CVD and up to 20% of patients who have undergone coronary artery bypass graft surgery are under major depression. Even mild depression, such as a depressed mood, can increase the risk of coronary artery disease. Restrictive measures taken during the COVID-19 pandemic might have increased depression in patients affected by cardiovascular diseases. According to MedTech Europe, around 95% of all COVID-19 deaths had at least one underlying condition, with cardiovascular disease being the leading comorbidity (65%). Also, around 50% decrease in the number of people visiting hospitals and other health care facilities with symptoms of heart attacks or stroke is creating a significant backlog of patients with severe health conditions. The pandemic has significantly negatively impacted the cardiometabolic diseases market in the short term. However, the market will grow at a moderate pace during the forecast period.
Eli Lilly and Company; Bayer AG; Arrowhead Pharmaceuticals, Inc; Novartis AG; Boehringer Ingelheim International GmbH; Novo Nordisk A/S; AstraZeneca; Alnylam Pharmaceuticals, Inc.; Cardax, Inc.; and Kowa Company, Ltd are among the leading companies operating in the cardiometabolic diseases market.
Cardiometabolic Diseases Market, by Region, 2021 (%)
Cardiometabolic Diseases Market Size & Opportunity 2028
Download Free Sample
Cardiometabolic Diseases Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Cardiovascular Disease (CVD), Type 2 diabetes, Hypertension, and Obesity), Treatment (ACE Inhibitors, Diuretics, Glucophage, and Others), Dosage (Tablet and Injection), Route of Administration (Oral and Intravenous), End Users (Hospital, Clinic, and Homecare Setting), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Geography
Cardiometabolic Diseases Market Size & Opportunity 2028
Download Free SampleCardiometabolic Diseases Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Cardiovascular Disease (CVD), Type 2 diabetes, Hypertension, and Obesity), Treatment (ACE Inhibitors, Diuretics, Glucophage, and Others), Dosage (Tablet and Injection), Route of Administration (Oral and Intravenous), End Users (Hospital, Clinic, and Homecare Setting), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Geography
Based on type, the cardiovascular diseases market is segmented into cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. Based on treatment, the market is segmented into ACE inhibitors, diuretics, Glucophage, and others. Based on dosage, the cardiometabolic diseases market is bifurcated into tablet and injection. By route of administration, the market is bifurcated into oral and intravenous. Based on end users, the cardiometabolic diseases market is segmented into clinic, hospital and homecare setting. By geography, the market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com